Individualized patient decision-aid for immunosuppressive drugs in women with lupus nephritis: study protocol of a randomized, controlled trial

Jasvinder A. Singh¹,²,³*, Nipam Shah² and Candace Green²

Abstract

Background: Systemic Lupus erythematosus (SLE), also commonly referred to as lupus, is a rare, but sometimes, fatal disease, that primarily affects young women. Lupus nephritis, a common manifestation of lupus, is more common and more devastating in patients of minority race/ethnicity. Patients have negative views of immunosuppressive drugs for lupus nephritis due to a concern about side effects and under-appreciation of its benefit. We designed a study to assess the effectiveness of individualized, computerized patient decision-aid for immunosuppressive drugs for lupus nephritis compared to a standard pamphlet for patient decision-making.

Methods: Adult women with lupus nephritis, with a current lupus nephritis flare or at risk of a future lupus nephritis flare will be randomized to individualized, computerized patient decision-aid for immunosuppressive drugs vs. standard pamphlet with information about lupus and its treatment including immunosuppressive drugs and outcomes. Patients will complete outcome assessments immediately after the intervention has been administered. Patients will be followed at 3-months with a brief survey, either in person or on the phone, and at 6-months with medical record review for exploratory outcomes. Co-primary outcomes are decisional conflict and informed choice regarding immunosuppressive drugs (combines values, knowledge and choice). Secondary outcomes include: (1) assessment of patient-physician communication by assessing audio-taped physician-patient communication after intervention administration; (2) concordance between patient’s desired and actual role in immunosuppressive drugs decision-making using the control preference scale (CPS); and (3) patient perception of physician interaction using the interpersonal process of care- short form (IPC-SF).

Discussion: This is one of the first studies to evaluate the effectiveness of an educational intervention targeting minorities with lupus nephritis. This patient-centered lupus nephritis decision-aid will be available in the public domain in English and Spanish.

Trial registration: ClinicalTrials.gov Identifier: NCT02319525; registered on November 5, 2014.

Keywords: Lupus, Lupus nephritis, Minorities, Women, Decision-aid, Randomized trial, Randomized controlled trial
Background
In the US, 161,000 individuals have definite SLE [1], making it a rare disease with a prevalence of 0.05%. However, lupus nephritis accounts for 2% of all end-stage renal disease in the U.S. [2], a proof of its devastating effect on kidneys, making it a serious disease. Compared to Whites, African-Americans and Hispanics not only have a higher incidence of lupus and higher associated mortality [3–6], but also a higher prevalence of lupus nephritis and worse renal outcome [6–14]. Thus, more research is needed in minorities with lupus nephritis. Research in rare diseases is an area of focus of patient-centered outcomes research institute (PCORI) funding.

Many racial/ethnic minority patients do not receive quality health care, due in part to lower health literacy and numeracy [15], and poorer physician-patient communication [16–19]. Compared to Caucasians, African-American women with lupus have a lower likelihood of accepting immunosuppressive drugs such as cyclophosphamide [20, 21]. Immunosuppressive drugs in combination with corticosteroids are the standard of care for induction treatment of lupus nephritis treatment rather than either medication alone; immunosuppressive drugs are also important in the maintenance phase of the treatment of lupus nephritis [22, 23].

There are many unanswered questions regarding the patient perception of immunosuppressive drugs in patients with lupus, especially in minority patients with lupus. To our knowledge, there is little or no evidence about whether interventions to change patient knowledge or perception regarding immunosuppressive drugs in lupus patients can improve decision-making regarding these treatments. Compared to Caucasians, studies show that African-Americans had lower numeracy, which explained poor chronic disease control in diabetes [24], and HIV medication regimen [25].

A decision-aid can provide information tailored to patients with low health literacy and numeracy. Therefore, the objective of this study is to compare the efficacy of the usual education materials to individualized computerized decision-aid (guide) to reduce the decision conflict regarding treatment decisions for immunosuppressive therapies in patients with lupus nephritis. Our long-term objective is to improve outcomes in patients with lupus.

Methods
Study overview and hypothesis
Some patients with lupus have negative views of immunosuppressive drugs (cyclophosphamide, mycophenolate mofetil, azathioprine, calcineurin inhibitors such as cyclosporine and tacrolimus etc.) and may reject consideration of these drugs for treatment of their lupus [26–29]. The rejection of immunosuppressive drugs may be related not on their values, but also to limited knowledge of efficacy of these drugs coupled with a fear of adverse events. As a result, many patients choose to use only corticosteroids rather than a combination of immunosuppressive drugs and corticosteroids, for the treatment of their active lupus nephritis. The combination is not only more effective than corticosteroids alone for lupus nephritis, but in many cases, may also be associated with similar or lower risk of adverse events [22, 23].

This study will test the effectiveness of a decision-aid regarding immunosuppressive drugs in patients with lupus nephritis, with a focus on minority race/ethnicity. It is a comparative effectiveness research (CER) study. The main study aim is to assess the effectiveness of an individualized computerized patient decision-aid focused on immunosuppressive drugs for lupus nephritis. Our hypotheses are that in patients with lupus nephritis, compared to usual care (educational pamphlet), individualized computerized decision-aid will be more effective, as indicated by a greater reduction in decisional conflict scores (Hypothesis 1) and a higher rate of informed choice favoring immunosuppressive drugs (concordance between values, knowledge and choice of immunosuppressive drugs; Hypothesis 2).

The study protocol is registered at the clinicaltrials.gov website, NCT02319525. All study visits, including screening, baseline visit and 3-month follow-up assessments will be done during patient’s regular scheduled clinic visits/appointments, with few exceptions, if any. This was done in order to keep the patient burden for study participation low and to encourage patients with lower socio-economic status and/or difficulty in transportation to participate in this research study focused at disadvantaged patients with limited resources.

Study design
This is a multicenter, parallel two-arm, prospective randomized trial comparing an individualized computerized decision-aid tool to an educational pamphlet (usual care). Patients with lupus nephritis attending clinics at the 4 recruiting sites will be recruited over a 2-year period starting January 2015. Local Institutional Review Board at each participating site, including the University of Alabama at Birmingham (UAB), approved the study procedures. This study was funded by a grant from the Patient Centered Outcomes Research Institute (PCORI).

Study population
We will oversample African American and Hispanic groups due to study’s focus on minorities, but other racial groups will also be recruited in the study. Patients with lupus nephritis will be enrolled from participating clinics at UAB, University of California at San Francisco, Baylor College of Medicine and Ohio State University. These sites were chosen based on high numbers of minority lupus patients, and a dedicated lupus clinic/service at each site. We will recruit two groups of patients, including patients with: (1) newly diagnosed active lupus
nephritis needing immunosuppressive therapy or a lupus nephritis flare despite current immunosuppressive therapy requiring a change in immunosuppressive drug/therapy (current lupus nephritis flare scenario); or (2) lupus nephritis with prior experience and/or discussion regarding immunosuppressive therapy for a past lupus nephritis flare, who are at the risk of a future lupus nephritis flare (future lupus nephritis flare scenario). Decisional conflict and informed choice were co-primary outcomes and secondary outcomes included patient decision-making and patient-physician communication.

**Study intervention**

The study intervention is an educational behavioral intervention targeting patient knowledge and opinions about immunosuppressive drugs. Active intervention includes an individualized, computerized decision-aid, developed specifically for this study, with a focus on minority women. The control intervention is a pamphlet with information about lupus and its treatment.

The decision-aid was developed in multiple steps incorporating the following elements: (1) comparative effectiveness data (benefits and common and uncommon harms) on immunosuppressive drugs with systematic reviews, meta-analysis and network meta-analysis (NMA) incorporating evidence from direct comparison studies and indirect comparisons [30–32]; (2) qualitative assessment of patient barriers an facilitators to decision-making regarding immunosuppressive medications [33, 34]; and (3) iterative testing and modification of the decision-aid by piloting in English- and Spanish speaking lupus patients at multiple study sites to ensure that words, phrases, messages and images used were acceptable and could be easily understood considering health literacy, numeracy and graphical literacy of the target population.

The decision-aid tool has been specifically designed in English and Spanish to assist patients with lupus nephritis make decisions regarding immunosuppressive drugs. The decision-aid will provide individualized information about immunosuppressive drugs specific to the each decision time point (induction vs. maintenance). We developed this tool for four probable scenarios based on the most common scenarios for a choice of immunosuppressive drugs (details in the section below). The decision-aid for each scenario will provide information about lupus in general, how lupus affects kidneys, benefits and side effects of using corticosteroids, general information (medication formulation, route of administration, costs of medication, dosage) and comparative risks and benefits about two immunosuppressive being compared, a final summary of the information provided and reference to other patient support groups. Patients are prompted to write down questions for their physician about these choices. The computerized decision-aid is programmed such that once the scenario is chosen by the coordinator per the guidance of the referring physician based on the most likely two choices (or a provider in the future), the decision-aid only shows that comparison.

Usual care or control group will receive a paper copy of the American College of Rheumatology pamphlet with information on lupus nephritis which is freely available online on the American College of Rheumatology website [35]. The pamphlet provides information about lupus in general, causes of lupus, how lupus is diagnosed and treated, broader health impact of lupus and living with lupus.

**Study procedures**

**Screening**

We will use International Classification of Diseases, ninth revision, common modification (ICD-9-CM) code for lupus, 710.0, to generate a list showing hospital clinic appointments of lupus nephritis patients, their gender and race/ethnicity each month. We will screen this list to identify potentially eligible individuals weekly, and discuss each patient’s potential eligibility for the study with the health care provider for their lupus care, ahead of their visit (Table 1, study eligibility criteria). We will also screen the lists of patients scheduled for lupus clinics at each institution, since each participating institution has a weekly lupus clinic. Male patients and patients with lupus but no evidence of lupus nephritis will be excluded. In addition, this study will be advertised in the rheumatology and nephrology clinics, to rheumatology and nephrology fellows and attending physicians, who frequently follow patients with lupus nephritis, and to renal pathologists at each institution. The study coordinator will examine clinic notes for eligibility criteria for patients referred to us by physicians, fellows or renal pathologists. We will find out the scheduled clinic appointments for these potentially eligible patients, and inform their treating physician about potential patient study enrollment on the day of the clinic.

| Table 1 Study eligibility criteria |
|-----------------------------------|
| **Inclusion criteria**             |
| 1. Females with lupus nephritis    |
| 2. Currently having a flare of lupus nephritis according to expert rheumatologist and considering change or initiation of an immunosuppressive medication for lupus nephritis (current flare) or had had flare of lupus nephritis in the past and have had experience or discussion of immunosuppressive medication for lupus nephritis who were at risk for a future flare (future flare) |
| 3. Age 18 years or older           |
| 4. All racial/ethnic groups        |
| **Exclusion Criteria**             |
| 1. Male patients with lupus nephritis |
| 2. Patients with lupus but no nephritis |
| 3. Patients having kidney flare but medication change is not considered |
| 4. Patients with end stage renal disease on dialysis |
| 5. Patients with a renal transplant or who are candidate for a renal transplant |
visit. To ensure timely patient enrollment, we will have regular meetings with rheumatology and nephrology attending physicians and fellows who primarily provide care to lupus patients, as well as send periodic emails to all providers. A brief overview of the study flow is provided in the CONSORT diagram (Fig. 1).

**Baseline visit: procedures at initial patient visit**

**Physician Designation of the treatment scenario and Informed Consent** Before obtaining informed consent from a study subject, the physician will be notified of the potential recruitment and asked to assign a scenario (medication group; details in the relevant section below) and whether the patient having a flare of lupus nephritis currently (current lupus nephritis flare scenario) or is at risk of a flare in the future (future lupus nephritis flare scenario). Study coordinator will then obtain a written informed consent.

**Randomization** After informed consent is obtained, subjects will be randomized using the Research Electronic Data Capture (REDCap) electronic data capture tool [36]. Once the randomization form is completed and saved, a unique participant identification number will be generated. Randomization will be stratified by study site and language (English vs. Spanish). Study coordinators will enter patients’ name, date of birth, gender, and recruitment site in the REDCap randomization form. A computer-generated algorithm will randomize assign study subjects to either decision-aid or pamphlet intervention groups in a 1:1 ratio. We will use a separate unique prefix for each site added to each patient identification number in order to identify subjects by study site.

**Pre-intervention assessment** After each subject is randomized, the study coordinator will administer assessments of health literacy using Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF) [37] and Short Assessment of Health Literacy (SAHL) [38] and graphical and numeric literacy to them. Study subjects will also respond to questions assessing knowledge and patient values about the immunosuppressive drugs for lupus nephritis as treatment options for them (current flare or future flare scenarios), and choose what treatment they prefer now for their current (or future) lupus nephritis flare. Pre-intervention assessments will evaluate primary outcomes such as decisional conflict scale [39] and patient’s choice of the immunosuppressive drug based on knowledge and values related to taking...
immunosuppressive drugs (informed choice; details in
the section on outcome measures below) [40, 41]. All
these assessments will be completed before administer-
ing the study intervention.

**Intervention and scenarios** Patients will read the educa-
tional material, i.e., decision-aid or the pamphlet, based on
the group they are randomized to, i.e., computerized
decision-aid or the pamphlet. This section provides details
of the intervention, and each intervention arm.

Decision-aid: In addition to the information on lupus
nephritis, the decision-aid will provide information on
four scenarios of choice between immunosuppressive
drugs. The scenarios were chosen by the patient’s lupus
care provider based on most likely choices for patient’s
treatment, based on either their current situation
(current flare) or anticipated future lupus nephritis flare
(future flare). Details are given below:

Scenario A (Treatment induction in immunosuppressive-
naive): This will be applicable to patients with newly diag-
nosed lupus nephritis or having history of lupus nephritis
with deteriorating renal function, who are currently not on
any immunosuppressive medication (current flare) or with
stable renal function currently not requiring immuno-
suppressive drug, but at the risk of future flare requiring in-
duction therapy (future flare). The decision-aid tool for this
scenario will provide information about two medication
choices: cyclophosphamide (cytoxan) and azathioprine
(Imuran).

Scenario B (Treatment maintenance in azathioprine fail-
ure): This will usually be applicable to patients with lupus
nephritis who are currently on azathioprine (Imuran) and
have deteriorating renal function (azathioprine failure;
current flare) or stable renal function on current azathi-
opr ine, but at the risk of future flare requiring change in
maintenance therapy (future flare). The decision-aid tool for
this scenario will provide information about two medication
choices: cyclophosphamide (cytoxan) vs. mycophenolate
mofetil (cellcept).

Scenario C (Treatment maintenance in azathioprine and
mycophenolate mofetil failure): This will usually be applic-
able to patients with lupus nephritis who have failed
azathioprine (Imuran) and mycophenolate mofetil (cellcept)
therapy and thus have signs of deteriorating renal function
(current flare) or stable renal function on current immuno-
suppressive maintenance therapy, but at the risk of future
flare requiring change in maintenance therapy (future flare).
The decision-aid tool for this scenario will provide information about two medication
choices: cyclophosphamide (cytoxan) vs. calcineurin
inhibitors (cyclosporine, tacrolimus etc.).

Scenario D (Treatment maintenance in mycophenolate
mofetil failure): This will usually be applicable to patients
with lupus nephritis who are currently on mycophenolate
mofetil (cellcept) and have deteriorating renal function
(cellcept failure; current flare) or stable renal function on
current mycophenolate mofetil maintenance therapy, but
at the risk of future flare requiring change in maintenance
therapy (future flare). The decision-aid tool for this
scenario will provide information about two medication
choices: cyclophosphamide (cytoxan) and azathioprine
(Imuran).

Pamphlet: This is a standard material available online
from the American College of Rheumatology (ACR) (3).
It will be provided as a paper pamphlet to the patient to
read and review. The pamphlet provides information
about lupus, symptoms of lupus, diagnosis of lupus, la-
boratory test for lupus and tips to control lupus in lay
language. It also provides web links to various support
groups for lupus.

**Post-intervention assessment, including the Audio
Taping of the Physician-patient Communication** After
the administration of the intervention, patients will have a
discussion with physicians about immunosuppressive drugs
(only current flare patients) and all study subjects will
complete the post-intervention assessment questionnaire.
This questionnaire will measure co-primary outcomes (de-
cision conflict and informed choice) as in pre-intervention
assessments. In addition to this, the post-intervention ques-
tionnaire will measure two secondary outcomes, i.e., the
control preference scale (CPS) [42–44] and interpersonal
process of care- short form (IPC-SF) [45]. Patient-physician
conversation will be audio taped for all patients with
current lupus nephritis flares (current flare patients), but
not future flare patients, and assessed as a secondary
outcome. The audio taped conversation constitutes one of
the three secondary outcomes.

**3-month phone vs. clinic follow-up assessment**
At 3 months, study subjects will respond to the IPC ques-
tionnaire. Subjects will respond to this questionnaire via
phone or during a routine clinic visit, if it coincides with
study follow-up date. When subjects are not reachable via
phone and not seen in clinic, the study coordinator will
mail the follow up questionnaire.

**6-month medical record follow-up assessment**
The site study coordinators will extract laboratory, medici-
cation and other clinical data on exploratory outcomes at
6 months using Electronic Health Record (EHR) at each
study site for patients currently having lupus nephritis
flare (current flare scenario), except missed/cancelled outpatient clinic visits which will be captured for all patients.
The exploratory outcomes include cumulative gluco-
corticoid dose, immunosuppressive medication adherence and persistence, serum creatinine and spot protein/cre-
atinine ratios, and the number of missed/cancelled clinic
appointments. We anticipate that due to the variation of the frequency and type of regular laboratory assessments of lupus nephritis across sites, there will be significant amount of missing data. We also anticipate that available laboratory data is likely to be collected at time points different from the 6-month study follow-up time-point, since these are being done as part of clinical care not as part of trial protocol, making it heterogeneous and sometimes not usable. We will attempt to analyze these data as rigorously as possible. We considered obtaining these data for our study, but patient stakeholders advised us to not add additional assessments or additional clinic or laboratory visits to capture outcomes not directly related to the study intervention.

Outcome measures

**Co-primary outcome measures**

Decisional Conflict Scale (DCS), low-literacy version: Decision conflict scale is a patient self-administered, validated measure of decisional conflict, most commonly used as the primary outcome in RCTs of decision-aid [46, 47]. We will assess the change in decisional conflict related to immunosuppressive drugs after the administration of the intervention at the baseline visit and compare the change from baseline between the groups (Table 2). The low literacy version consists of 10 items with 3 response categories (yes, unsure, no) with overall score of 0 (no decisional conflict) to 100 (extreme decisional conflict) [48]. Responses are given the following score values: yes = 0; unsure = 2; no = 4. Ten items are summed and multiplied by 2.5 to provide a score ranging 0-100. It is available in English and Spanish versions. Decisional conflict represents a state of uncertainty about a choice or course of action and is more likely in situations involving high-stakes choices with important potential gains and losses, value tradeoffs in selecting a choice or a course of action (vs. the alternative) or uncertain outcomes. The DCS scale also has 4 subscales: (1) Uncertainty subscore: Scores range from 0 (feels extremely certain about best choice) to 100 (feels extremely uncertain about best choice); (2) Informed subscore: Scores range from 0 (feels extremely informed) to 100 (feels extremely uninformed); (3) Values Clarity subscore: Scores range from 0 (feels extremely clear about personal values for benefits and risks/side effects) to 100 (feels extremely unclear about personal values for benefits and risks/side effects); and (4) Support subscore: Scores range from 0 (feels extremely supported in decision making) to 100 (feels extremely unsupported in decision making). DCS subscale scores will be explored, if data are available for comparisons.

**Informed choice** We will assess informed choice by using a validated multidimensional model of informed choice [40, 41] that individually assesses and then combines three constructs: values regarding immunosuppressive drugs, knowledge about immunosuppressive drugs, and treatment choices. We will assess informed choice after patient has viewed the decision-aid or lupus pamphlet at the baseline study visit before any treatment decision-making. Values will be assessed with a list consisting of patients’ views regarding immunosuppressive drugs as treatment option and their side effects generated by us based on patient concerns about regarding immunosuppressive drugs. The values statements consisted of both positive and negative values about immunosuppressive drugs, mixed in a random order, with responses ranging from strongly disagree to strongly agree. We will score positive and negative value statements with appropriate signs (+ or −) and aggregate into a total score. A higher total score will indicate more positive values regarding using immunosuppressive drugs and a median score (or an overall more positive vs. more negative values) will be used to classify values as positive vs. negative regarding using immunosuppressive drugs. Knowledge regarding immunosuppressive drugs for lupus nephritis were assessed using 20 questions and considered “adequate knowledge” if patients answer at least 75% of questions correctly. Choice will be assessed based on response to a single item on a nominal scale with anchors of start vs. don’t start immunosuppressives and “uncertain”

| Table 2 Study Outcomes and Outcome measures |
|--------------------------------------------|
| **Co-Primary outcomes** | **Time of assessment** | **Description** |
| Change in Decisional Conflict Scale (DCS) score [39, 46–48, 64]/Baseline post-intervention | 10-item patient-reported scale for lower literacy populations with 3-level response categories |
| Informed choice [40, 41]/Baseline post-intervention | Concordance between patient’s values related to taking immunosuppressive drugs and patients’ decision to start immunosuppressive drugs in those with adequate knowledge about immunosuppressive drugs |
| Secondary outcomes | | |
| Control Preferences Scale [51]/Baseline post-intervention | 2-item patient-reported assessment of whether the decision-making concordant with patient’s preference about their role |
| Interpersonal Processes of Care [45]/Baseline post-intervention | 18-item patient-reported multidimensional measure of physician-patient communication |
| Audiotaped Patient-physician discussion [56]/Baseline post-intervention | Active Patient Participation Coding Scheme decoding speech acts indicating patient participation and whether physician communication was patient-centered |
in the middle and 15 circles, asking patient’s choice in response to a question “if your doctor asked you right now to make a choice about immunosuppressives, please show where you would be on the scale below by choosing a circle below”. Informed choice refers to a choice that is based on accurate knowledge and is concordant with one's values. A higher proportion indicates more patients with informed choice regarding immunosuppressive drugs.

**Secondary outcome measures**

**Control preferences Scale** This validated measure will assess patient participation in decision-making for patients with lupus nephritis flare (current flare scenario patients only). This assesses how much decision-making control patients would like to have versus actually experienced by each patient. It determines the correlation between patient satisfaction with care and discriminates between those who feel involved in the decision versus not [42–44]. There are 5 responses for 5 control options: active, active shared, collaborative, passive shared and passive, which will be categorized as active (combining active and active shared), collaborative and passive (combining passive and passive shared), as previously [49–51]. We will examine for concordance between desired and actual roles played by patients with lupus nephritis flare (current flare scenario). A higher concordance in roles (desired vs. actually played) indicates that more patients experienced the desired role in decision-making.

**Patient physician communication and care processes** This will be assessed using the Interpersonal Processes of Care Short Form (IPC-SF), an 18-item validated patient-reported measure of patient-physician communication and care processes [45, 52–55]. IPC-SF is available in both English and Spanish versions.

**Analysis of Audiotaped physician-patient interaction** This will be done recording the patient physician discussion about immunosuppressive drugs and using the Active Patient Participation Coding Scheme (APPC), a validated instrument to assess indicators and facilitators of patient participation [56], for patients with a current lupus nephritis flare (current flare scenario). Three types of speech acts will be coded as active patient participation, because of their potential to influence a doctor’s behavior as well as the content and structure of the consultation [57–60], namely, question-asking, assertive responses, and expressions of concern. In addition, physician communication will be coded using speech acts such as supportive talk and partnership building. Trained coders will transcribe and recognize active participation with ‘utterance’ as the unit of analysis (the oral analogue of a simple sentence, independent clause), which will be summed for each interaction to create a frequency of the degree of active participation.

**Exploratory outcome measures**

We will assess the following exploratory outcomes, where data are available. Most exploratory outcomes are applicable only to patients with current flare scenarios, except missed/cancelled appointments (current flare or future flare scenario). Outcomes include cumulative glucocorticoid dose, medication adherence and persistence with immunosuppressive drugs, renal function as assessed by spot protein/creatinine ratios, serum creatinine, 24-h proteinuria, proportion with complete or partial renal remission, number of missed or cancelled clinic appointments.

We will also assess the acceptability of study intervention using an acceptability survey [61], as in previous studies [62]. Patients will rate the quality and the quantity of the information presented in decision aids (4-point scale ranging from “excellent” to “poor”) and rate the appropriateness of amount of information (responder burden), presentation style and helpfulness. Feasibility will be assessed by the amount of assistance required in navigating decision aids (none, a little, some, a lot) and with a self-administered satisfaction questionnaire [63]. Patients will rate satisfaction with decision aids on a 5-point Likert scale ranging from strongly agree to strongly disagree: Easy to use, practical, process did not take too long, easy to understand, did not mind spending extra time.

**Statistical analyses**

**Sample size calculation**

Our study has an adequate power to assess the treatment effect for the co-primary outcomes, with an estimated enrollment of 200 patients. We anticipate that 100 African-American and 100 Hispanic/Caucasian females will lupus nephritis be enrolled in the trial. Allowing 10% loss to follow-up, this sample size will provide 80% power for co-primary outcomes. We will be able to detect a moderate effect size difference between group means on decisional conflict (range 0–100) using a two sample t-test and two tailed type I error rate of 0.05 (hypothesis 1) [48, 64] and a 15% absolute difference in the proportion of patients with informed choice using a one-sided type I error rate of 0.05 (hypothesis 2) [65].

**Analysis of outcomes measures**

We will compare demographic variables and baseline characteristics between decision-aid and pamphlet groups, including health, numeric and graphical literacy by comparing mean values or proportions as appropriate. Measures of variability (standard deviation) will be calculated. We will
compare primary and secondary outcome measures using Student t test or analysis of variance or comparison of proportions. A two-sided p-value < 0.05 will be considered significant. We will stratify variables based on language (English/Spanish) and study sites and compare these variables using chi-square test or Fisher's exact test. All statistical analyses will be carried out using SAS, v9.4 (Cary, NC). We will also use logistic or linear regression to assess other predictors of each of the co-primary outcomes, including the intervention.

Study limitations
Our study has several limitations. We are assessing two co-primary outcomes. We chose these two co-primary outcomes, since they capture two complimentary aspects of decision-making, related to our intervention, an individualized decision-aid. If our intervention, an individualized decision-aid, is found to be effective, we will not know as to which individual component/message, led to the reduction in decision conflict or more informed choice. However, this is not a critical question to answer at this time, since as an educational intervention, our decision-aid is easy to implement. Since our decision-aid will be available in public domain, it would be available for any patient to use, and can be further modified to be contextually relevant. Another limitation is that while we have the decision aid and outcome instruments in English and Spanish, we do not have translations in other languages. This can be done in the future, and will make this decision-aid even easier to use for lupus patients who speak languages other than English and Spanish. In order to reduce the patient burden, we will not assess patient satisfaction and quality of life in this study. Therefore, the effect of this decision-aid on these domains will need to be examined in future studies.

Discussion
This study is a 2-arm parallel group trial of a behavioral patient educational intervention on patient decision-making in women with lupus nephritis, with a focus on minority race/ethnicity. Decision-making for immunosuppressive medications is a challenge in the treatment of patients with lupus nephritis, especially in racial minorities, who have more severe disease and worse outcomes. Previous studies have shown that there are both knowledge gaps related to immunosuppressive drugs as well as patient views that do not favor the use of immunosuppressive medications in lupus nephritis [26–29]. To our knowledge, there are no trials of educational or behavioral interventions and few studies of interventions in minority patients with lupus nephritis, if any. Therefore, our study that investigates if a patient-centered, individualized, easy to use intervention can reduce conflict in patient decisions and improve patient decision-making regarding immunosuppressive drugs for lupus nephritis, will fill an important knowledge gap.

Conclusion
In conclusion, by its focus on the minority lupus patients who deal with a life-threatening complex illness with severe morbidity at a young age, our study results will pave the way for other studies of computerized patient decision-aid not only in lupus nephritis, but also for other similar complex illnesses (common and rare) with significant morbidity and mortality risk. This decision-aid will be in the public domain, available free of charge to everyone, for a free online download.

Trial status
The study is ongoing. We are currently following patients enrolled at the four study sites.

Abbreviations
ACR: American college of rheumatology; CER: Comparative effectiveness research; CPS: Control preferences scale; DCS: Decision conflict scale; ICD-9-CM: International classification of diseases, ninth revision, common modification; IPC: Interpersonal processes of care; RCT: Randomized controlled trial; REALM-SF: Rapid estimate of adult literacy in medicine-short form; SAHL: SD short assessment of health literacy; SLE: Systemic lupus erythematosus; UAB: University of Alabama at Birmingham

Acknowledgements
We thank our colleagues from nephrology, pathology and rheumatology for referring patients to us, including Dr. Huma Fatima at UAB. We also thank our patients for study participation, and for providing us with valuable time and information, that has helped us advance science in patient-centered research.

Funding
This research was made possible by Grant from Patient Centered Outcomes Research Institute (PCOR; Grant Number CE-1304-6631), and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Patient-Centered Outcomes Research Institute.

Availability of data and materials
Not applicable.

Authors’ contributions
JAS developed the study design and drafted the study protocol as first author. NS and CG participated in patient enrollment in the study and data collection. JAS, NS and CG created a draft of this manuscript and revised it critically. All authors read and approved the final manuscript.

Author’s information
JAS is the co-chair of the special interest group assessing the outcome measures in arthroplasty and has served as expert/lead on task forces for the specialty societies, the U.S. Food and Drug Administration (FDA) and the Agency for Health Care Research and Quality (AHRQ). Each author certifies that his or her institution has approved the human protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research.

“The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.”

Competing interests
JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Bioiberica, Crealta, and Allergan. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity.
JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop, and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is a member of the Editorial Board of BMC Musculoskeletal Disorders. Other authors have no relevant conflict.

Consent to publication
Not applicable.

Ethics approval and consent to participate
The Institutional Review Boards at the University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA, the University of California at San Francisco (UCSF), San Francisco, California, the Baylor College of Medicine (BCM), Houston, Texas and the Ohio State University (OSU), Columbus, Ohio, approved this study. Each patient provided written informed consent to participate in the study. The trial protocol has been registered at Clinicaltrials.gov website at https://clinicaltrials.gov/ct2/show/NCT02319525 (NCT 02319525).

Author details
1Rheumatology Section, Medicine Service, VA Medical Center, Birmingham, AL, USA. 2Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 3Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.

Received: 6 December 2016 Accepted: 14 January 2017
Published online: 31 January 2017

References
1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part I. Arthritis Rheum. 2008;58(1):15–25.
2. Maisonneuve P, Agodoa L, Lellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35(1):157–65.
3. Odutola J, Ward MM. Ethnic and socioeconomic disparities in health among patients with rheumatic disease. Curr Opin Rheumatol. 2005;17(2):147–52.
4. Alarcon GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus in Minority populations: Nature vs. Nurture. Lupus. 1999;8(3):197–202.
5. Trends in deaths from systemic lupus erythematosus-United States, 1979–1998. MMWR Morb Mortal Wkly Rep. 2002;51(17):371–4.
6. Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis. 2006;65(1):1500–5.
7. Alarcon GS, Mcgwin Jr G, Pettit M, Reveille JD, Ramsey-Goldman R, Kimberly RP. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002;11(2):95–101.
8. Dooley MA, Aranow C, Grizler EM. Review of ACR renal criteria in systemic lupus erythematosus. Lupus. 2004;13(11):857–60.
9. Kastanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine. 2006;85(3):147–56.
10. Ward MM, Pyan E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med. 1996;156(12):3374–4.
11. Costenbader KH, Desai A, Alarcon GS, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63(8):1681–8.
12. Bernatsky S, Bolvin JF, Joseph L, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum. 2005;53(3):781–4.
13. Cervera R, Khamashia MT, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003;82(5):239–308.
14. Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003;18(10):2039–46.
15. Langford AT, Resnicow K, Roberts JS, Zikmund-Fisher BJ. Racial and ethnic differences in direct-to-consumer genetic tests awareness in HINTS 2007: sociodemographic and numeracy correlates. J Genet Couns. 2012;21(3):440–7.
16. Cene CW, Roter D, Carson KA, Miller 3rd ER, Cooper LA. The effect of patient race and blood pressure control on patient-physician communication. J Gen Intern Med. 2009;24(9):1057–64.
17. Gordon HS, Street Jr RL, Kelly PA, Souchek J, Way NP. Physician-patient communication following invasive procedures: an analysis of post-angiogram consultations. Soc Sci Med. 2005;61(10):1025–35.
18. Johnson RL, Roter D, Powe NR, Cooper LA. Patient race/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health. 2004;94(12):2084–90.
19. Manfredi C, Kaiser K, Matthews AK, Johnson TP. Are racial differences in patient-physician cancer communication and information explained by background, predisposing, and enabling factors? J Health Commun. 2010;15(3):272–9.
20. Vina ER, Masi CM, Green SL, Utset TO. A study of racial/ethnic differences in treatment preferences among lupus patients. Rheumatology (Oxford). 2012;51(9):1697–706.
21. Vina ER, Utset TO, Hannon MJ, Masi CM, Roberts N, Kwoh CK. Racial differences in treatment preferences among lupus patients: a two-site study. Clin Exp Rheumatol. 2014;32(6):680–6.
22. Tsang ASMW, Bulink E. Systemic lupus erythematosus: review of synthetic drugs. Expert Opin Pharmacother. 2015;16(18):2793–806.
23. Canetta PA, Bomback AS, Radhakrishnan J. Treating lupus in the kidney: where are we now, and where are we going? Discov Med. 2011;12(65):341–9.
24. Osborn CY, Cavanaugh K, Wallston KA, White RO, Rothman RL. Diabetes numeracy: an overlooked factor in understanding racial disparities in glycemic control. Diabetes Care. 2009;32(9):1614–9.
25. Waldrop-Valverde D, Osborn CY, Rodriguez A, Rothman RL, Kumar M, Jones DL. Numeracy skills explain racial differences in HIV medication management. AIDS Behav. 2010;14(4):799–806.
26. Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266–71.
27. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913–9.
28. Kumar K, Gordon C, Barry R, Shaw K, Home R, Raza K. It’s like taking poison to kill poison but I have to get better: a qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus. 2012;20(8):837–44.
29. Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum. 2002;47(6):630–8.
30. Singh JA, Hossain A, Kotb A, Wells GA. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Syst Rev. 2016;5(1):155.
31. Singh JA, Hossain A, Kotb A, Wells GA. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. J Rheumatol. 2016;1:150041.
32. Singh JA, Qu H, Yazdany J, Chatham W, Shewchuk R. Minorities with lupus nephritis and medications: a study of facilitators to medication adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum. 2007;56(6):1986–93.
33. Singh JA, Qu H, Yazdany J, Dallera M, Shewchuk RM. Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. J Rheumatol. 2015;42(9):1616–23.
34. Rheumatology ACo. 2016. http://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Lupus. Accessed 20 Jan 2017.
35. Singh JA, Hossain A, Kotb A, et al. Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis. J Rheumatol. 2016;1:150041.
36. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
37. Arozullah AM, Yarnold PR, Bennett CL, et al. Development and validation of a short-form, rapid estimate of adult literacy in medicine. Med Care. 2007;45(11):1026–33.
38. Lee SY, Stucky BD, Lee JY, Rozier RG, Bender DE. Short Assessment of Health Literacy-Spanish and English: a comparable test of health literacy for Spanish and English speakers. Health Serv Res. 2010;45(4):1105–20.
39. O’Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995;15(1):25–30.
40. Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect. 2001;4(2):99–108.
41. Michie S, Dormandy E, Marteau TM. The multi-dimensional measure of informed choice: a validation study. Patient Educ Couns. 2002;48(1):87–91.
42. Degner LF, Russell CA. Preferences for treatment control among adults with cancer. Res Nurs Health. 1988;11(6):367–74.
43. Degner LF, Kristjanson L, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA. 1997;277(18):1485–92.
44. Adams JR, Drake RE, Wolford GL. Shared decision-making preferences of people with severe mental illness. Psychiatr Serv. 2007;58(9):1219–21.
45. Stewart AL, Napoles-Springer AM, Gregorich SE, Santoyo-Olsson J. Interpersonal processes of care survey: patient-reported measures for diverse groups. Health Serv Res. 2007;42(3 Pt 1):1235–56.
46. O’Connor AM. User Manual - Decisional Conflict Scale (10 item question format) [document on the Internet]. © 1993 [updated 2010; cited YYYY MM DD]. 16 p. 2010. Available from https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf. Ottawa Hospital Research Institute; Ottawa Hospital Research Institute. Accessed 20 Jan 2017.
47. Siminoff LA, Raudin P, Colabianchi N, Sturm CM. Doctor-patient communication patterns in breast cancer adjuvant therapy discussions. Health Expect. 2003;3(1):26–36.
48. O’Connor AM. User Manual-Decisional Conflict Scale. © 1993 [updated 2010], vol. 2012. 2003. Available from https://decisionaid.ohri.ca/index.html. http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf.
49. Degner LF, Sloan JA, Venkatapathy P. The Control Preferences Scale. Can J Nurs Res. 1997;29(3):21–43.
50. Florin J, Ehrenberg A, Ehnfors M. Clinical decision-making: predictors of patient participation in nursing care. J Clin Nurs. 2008;17(21):2935–44.
51. Singh JA, Sloan JA, Atherton PJ, et al. Preferred roles in treatment decision making among patients with cancer: a pooled analysis of studies using the Control Preferences Scale. Am J Manag Care. 2010;16(9):689–90.
52. Stewart AL, Napoles-Springer A, Perez-Stable EJ. Interpersonal processes of care in diverse populations. Milbank Q. 1999;77(3):305–27.
53. Schillinger D, Handley M, Wang F, Hammer H. Effects of self-management support on structure, process, and outcomes among vulnerable patients with diabetes: a three-arm practical clinical trial. Diabetes Care. 2009;32(4):559–66.
54. Naples AM, Gregorich SE, Santoyo-Olsson J, O’Brien H, Stewart AL. Interpersonal processes of care and patient satisfaction: do associations differ by race, ethnicity, and language? Health Serv Res. 2009;44(4):1326–44.
55. Schener Y, Stewart A, Na B, Whooley MA. Depressive symptoms and perceived doctor-patient communication in the Heart and Soul study. J Gen Intern Med. 2009;24(5):550–6.
56. Street Jr RL, Millay B. Analyzing patient participation in medical encounters. Health Commun. 2001;13(1):61–73.
57. Cegala DJ, Street Jr RL, Clinch CR. The impact of patient participation on physicians’ information provision during a primary care medical interview. Health Commun. 2007;21(2):177–85.
58. Krivitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995–202.
59. Street Jr RL, Gordon H, Haidet P. Physicians’ communication and perceptions of patients: is it how they look, how they talk, or is it just the doctor? Soc Sci Med. 2007;65(3):586–98.
60. Street Jr RL, Richardson MN, Cox V, Suarez-Almazor ME. (Mis)understanding in patient-healthcare provider communication about total knee replacement. Arthritis Rheum. 2006;54(1):100–7.
61. Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med. 2009;169(17): 1560–8.
62. Fraenkel L, Peters E, Charpentier P, et al. Decision tool to improve the quality of care in rheumatoid arthritis. Arthritis Care Res. 2012;64(7):977–85.
63. Saag KG, Mohr PE, Esmail L, et al. Improving the Efficiency and Effectiveness of Pragmatic Clinical Trials in Older Adults in the United States. [In press]. Contemporary Clinical Trials. 2012.
64. Cohan D, Gomez E, Greenberg M, Washington S, Charlebois ED. Patient perspectives with abbreviated versus standard pre-test HIV counseling in the prenatal setting: a randomized-controlled, non-inferiority trial. PLoS One. 2009;4(9):e7166.
65. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffery KJ. A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. BMJ. 2010;341:c5370.